Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

BACKGROUND: In this study we aimed to evaluate the efficacy and safety of the PD-L1 inhibitor durvalumab across various mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumours in the Drug Rediscovery Protocol (DRUP). This is a clinical study in which patients are treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Geurts, Birgit S., Battaglia, Thomas W., van Berge Henegouwen, J. Maxime, Zeverijn, Laurien J., de Wit, Gijs F., Hoes, Louisa R., van der Wijngaart, Hanneke, van der Noort, Vincent, Roepman, Paul, de Leng, Wendy W. J., Jansen, Anne M. L., Opdam, Frans L., de Jonge, Maja J. A., Cirkel, Geert A., Labots, Mariette, Hoeben, Ann, Kerver, Emile D., Bins, Adriaan D., Erdkamp, Frans G.L., van Rooijen, Johan M., Houtsma, Danny, Hendriks, Mathijs P., de Groot, Jan-Willem B., Verheul, Henk M. W., Gelderblom, Hans, Voest, Emile E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985217/
https://www.ncbi.nlm.nih.gov/pubmed/36870947
http://dx.doi.org/10.1186/s12885-023-10663-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985217/
https://www.ncbi.nlm.nih.gov/pubmed/36870947
http://dx.doi.org/10.1186/s12885-023-10663-2

Ejemplares similares